EXHIBIT A

CIRRICULUM VITAE

MATTHEW CLAYTON COFFEY

Date of birth:	9 March 1971
Place of birth:	Medicine Hat, Alberta
Citizenship:	Canadian
Marital Status:	Married
Address:	Oncolytics Biotech Inc. 210, 1167 Kensington Crescent NW Calgary, Alberta T2N 1X7
	Bus: (403) 670-0711 Res: (403) 244-8373 Fax: (403) 283-0858 Email: mattonc@aol.com

Degrees

1998	Ph.D., University of Calgary, (Oncology)
1993	B.Sc., University of Calgary, (Cellular, Molecular, & Microbial Biology)

Courses

Sept/2002	Classroom Patent Bar Review, Patent Resources Group, Glendale, CA
July/2002	Introduction to Good Clinical Practices & Auditing, Drug Information Association, Montreal, PQ
May/2002	Patent Law for Managers, Engineers & Scientists, Patent Resources Group, Florida
Feb/2002	Clinical Trials for Anti-Cancer Drugs, Institute for International Research, San Francisco, CA
Jun/2001	Mastering Clinical Research Project Management in Canada, Institute for International Research, Toronto, Ontario
Apr/2001	Patent Law for Managers, Engineers, and Scientists, The Center for Professional Advancement, East Brunswick, NJ

Positions

Jul/99-present	Vice President, Product Development, Oncolytics Biotech Inc.
Jul/99-May/00	Chief Financial Officer, Oncolytics Biotech Inc.
Mar/99-Jul/99	Project Manager, Synsorb Biotech Inc.
Apr/98-Apr/99	Co-founded Oncolytics Biotech Inc. Appointed Corporate Secretary

Awards

1994-8	Alberta Heritage Foundation for Medical Research (AHFMR)

Publications

1. Hirasawa K, Nishikawa SG, Norman KL, **Coffey MC**, Thompson BG, Yoon CS, Waisman DM, Lee PW. Systemic reovirus therapy of metastatic cancer in immunecompetent mice. Cancer Res 2003 Jan 15;63(2): 348-53

2. Morris DG, Forsyth PA, Paterson AH, Fonseca K, Difrancesco LM, Thompson BG, **Coffey MC**, Tom Baker Cancer Centre, Calgary, Ab; Oncolytics Biotech Inc., Calgary, Ab. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proceedings of ASCO Volume 21 2002.

3. Lakshminarayanan S, Wu F, **Coffey M**, Thompson B, Kodihalli S, BioReliance Corporation, Rockville MD; Oncolytics Biotech Inc., Calgary, Ab. Scalable Purification Procedure for Reolysin for Cancer Therapy

4. Norman KL, **Coffey MC**, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW. Reovirus Oncolysis of Human Breast Cancer. Human Gene Therapy 2002 March 20

5. Zhao YG, Gilmore R, Leone G, **Coffey MC**, Weber B, Lee PW. Hsp90 phosphorylation is linked to its chaperoning function: Assembly of the reovirus cell attachment protein. J Biol Chem 2001 Jul 3

6. **Coffey, MC**, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998 Nov 13; 282 (5392):1244-6

7. Strong JE, **Coffey MC**, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis; usurpation of the Ras signaling pathway by reovirus. EMBO J 1998 Jun 15;17(12):3351-62

8. Gilmore R, **Coffey MC**, Lee PW. Active participation of Hsp90 in the biogenesis of the trimeric reovirus cell attachment protein sigma1. J Biol Chem 1998 Jun 12;273(24);15227-33

9. Gilmore R, **Coffey MC**, Leone G, McLure K, Lee PW. Co-translational trimerization of the reovirus cell attachment protein. EMBO J 1996 Jun 3;15(11):2651-8

10. Leone G, **Coffey MC**, Gilmore R, Duncan R, Maybaum L, Lee PW. C-terminal trimerization, but not N-terminal trimerization, of the reovirus cell attachment protein is a posttranslational and Hsp70/ATP-dependent process. J Biol Chem 1996 Apr 5;271(14):8466-71

11. Lakshminarayanan S, Huang M, Kodihalli S, **Coffey MC**, Thompson B, Wu F. Production and purification of Reolysin ® for cancer therapy. Abstract 942

Patents

1. United States Patent No. 6,649,157, Thompson BG, **Coffey MC,** Viruses for the treatment of cellular proliferative disorders.

2. United States Patent No. 6,576,234, Thompson BG, **Coffey MC,** Reovirus for the treatment of neoplasia

3. United States Patent No. 6,565,831, Thompson BG, **Coffey MC,** Method of preventing reovirus recognition for the treatment of cellular

4. United States Patent No. 6,528,305, Thompson BG, **Coffey MC** Method of producing infectious reovirus

5. United States Patent No. 6,455,038, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of cellular proliferative disorders

6. European Patent No. 1,003,524, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia

7. United States Patent No. 6,344,195, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia

8. New Zealand Patent No. 337493, Oncolytics Biotech Inc.: Reovirus for the treatment of neoplasia

9. United States Patent No. 6,261,555, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia

10. United States Patent No. 6,110,461, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of neoplasia

11. United States Patent No. 6,136,307, Lee PW, Strong J, **Coffey MC** Reovirus for the treatment of cellular proliferative disorders

12. United States Patent No. 6,808,916, **Coffey MC**, Thompson BG, Method of Extracting Virus From Cell Culture

13. United States Patent No. 6,811,775, Lee PW, Strong J, **Coffey MC** Reovirus for the Treatment of Cellular Proliferative Disorders